Erythrocytes From Patients With Type 2 Diabetes Induce Endothelial Dysfunction Via Arginase I

Journal of the American College of Cardiology

Volumn 72, Issue 7, 2018, Pages 769-780

  Zhou, Zhichao ^a   Mahdi, Ali ^a   Tratsiakovich, Yahor ^a   Zahorán, Szabolcs ^b   Kövamees, Oskar ^a   Nordin, Filip ^a   Uribe Gonzalez, Arturo Eduardo ^c   Alvarsson, Michael ^c   Östenson, Claes Göran ^c   Andersson, Daniel C ^a,c   Hedin, Ulf ^c   Hermesz, Edit ^b   Lundberg, Jon O ^c   Yang, Jiangning ^a   Pernow, John ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF SZEGED   (Hungary)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

arginase; endothelial dysfunction; reactive oxygen species; red blood cell; type 2 diabetes; vascular complication

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGINASE; ARGINASE 1; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; METFORMIN; REACTIVE OXYGEN METABOLITE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; ARGINASE I, HUMAN; ENZYME INHIBITOR; VASODILATOR AGENT;

ADULT; AORTA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; INTERNAL MAMMARY ARTERY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE CELL; UPREGULATION; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; METABOLISM; MIDDLE AGED; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VASODILATATION;

AGED; ANIMALS; ARGINASE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; ERYTHROCYTES; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGAN CULTURE TECHNIQUES; RATS; REACTIVE OXYGEN SPECIES; VASODILATION; VASODILATOR AGENTS;

EID: 85050679286     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.05.052     Document Type: Article

References (20)

1. Vanhoutte, P.M., Shimokawa, H., Tang, E.H., Feletou, M., Endothelial dysfunction and vascular disease. Acta Physiol (Oxf) 196 (2009), 193–222.
2. Palmer, S.C., Mavridis, D., Nicolucci, A., et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 316 (2016), 313–324.
3. Pernow, J., Jung, C., The emerging role of arginase in endothelial dysfunction in diabetes. Curr Vasc Pharmacol 14 (2016), 155–162.
4. Shemyakin, A., Kovamees, O., Rafnsson, A., et al. Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation 126 (2012), 2943–2950.
5. Kovamees, O., Shemyakin, A., Checa, A., et al. Arginase inhibition improves microvascular endothelial function in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 101 (2016), 3952–3958.
6. Cortese-Krott, M.M., Rodriguez-Mateos, A., Sansone, R., et al. Human red blood cells at work: identification and visualization of erythrocytic eNOS activity in health and disease. Blood 120 (2012), 4229–4237.
7. Sprague, R.S., Bowles, E.A., Achilleus, D., Stephenson, A.H., Ellis, C.G., Ellsworth, M.L., A selective phosphodiesterase 3 inhibitor rescues low PO2-induced ATP release from erythrocytes of humans with type 2 diabetes: implication for vascular control. Am J Physiol Heart Circ Physiol 301 (2011), H2466–H2472.
8. Wautier, J.L., Wautier, M.P., Schmidt, A.M., et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A 91 (1994), 7742–7746.
9. Yang, J., Gonon, A.T., Sjoquist, P.O., Lundberg, J.O., Pernow, J., Arginase regulates red blood cell nitric oxide synthase and export of cardioprotective nitric oxide bioactivity. Proc Natl Acad Sci U S A 110 (2013), 15049–15054.
10. Bizjak, D.A., Brinkmann, C., Bloch, W., Grau, M., Increase in red blood cell-nitric oxide synthase dependent nitric oxide production during red blood cell aging in health and disease: a study on age dependent changes of rheologic and enzymatic properties in red blood cells. PLoS One, 10, 2015, e0125206.
11. Jiang, M., Jia, L., Jiang, W., et al. Protein disregulation in red blood cell membranes of type 2 diabetic patients. Biochem Biophys Res Commun 309 (2003), 196–200.
12. Ostenson, C.G., Khan, A., Abdel-Halim, S.M., et al. Abnormal insulin secretion and glucose metabolism in pancreatic islets from the spontaneously diabetic GK rat. Diabetologia 36 (1993), 3–8.
13. Kovamees, O., Shemyakin, A., Pernow, J., Amino acid metabolism reflecting arginase activity is increased in patients with type 2 diabetes and associated with endothelial dysfunction. Diab Vasc Dis Res 13 (2016), 354–360.
14. Beleznai, T., Feher, A., Spielvogel, D., Lansman, S.L., Bagi, Z., Arginase 1 contributes to diminished coronary arteriolar dilation in patients with diabetes. Am J Physiol Heart Circ Physiol 300 (2011), H777–H783.
15. Jiang, M., Ding, Y., Su, Y., Hu, X., Li, J., Zhang, Z., Arginase-flotillin interaction brings arginase to red blood cell membrane. FEBS Lett 580 (2006), 6561–6564.
16. Savu, O., Iosif, L., Bradescu, O.M., Serafinceanu, C., Papacocea, R., Stoian, I., L-arginine catabolism is driven mainly towards nitric oxide synthesis in the erythrocytes of patients with type 2 diabetes at first clinical onset. Ann Clin Biochem 52 (2015), 135–143.
17. Gupta, B.L., Preet, A., Baquer, N.Z., Protective effects of sodium orthovanadate in diabetic reticulocytes and ageing red blood cells of Wistar rats. J Biosci 29 (2004), 73–79.
18. Chuaiphichai, S., McNeill, E., Douglas, G., et al. Cell-autonomous role of endothelial GTP cyclohydrolase 1 and tetrahydrobiopterin in blood pressure regulation. Hypertension 64 (2014), 530–540.
19. Drummond, G.R., Sobey, C.G., Endothelial NADPH oxidases: which NOX to target in vascular disease?. Trends Endocrinol Metab 25 (2014), 452–463.
20. Chaudhury, A., Duvoor, C., Reddy Dendi, V.S., et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne), 8, 2017, 6.